ECSP22026478A - Inhibidor de diacilglicerol aciltransferasa 2 - Google Patents

Inhibidor de diacilglicerol aciltransferasa 2

Info

Publication number
ECSP22026478A
ECSP22026478A ECSENADI202226478A ECDI202226478A ECSP22026478A EC SP22026478 A ECSP22026478 A EC SP22026478A EC SENADI202226478 A ECSENADI202226478 A EC SENADI202226478A EC DI202226478 A ECDI202226478 A EC DI202226478A EC SP22026478 A ECSP22026478 A EC SP22026478A
Authority
EC
Ecuador
Prior art keywords
diacylglycerol
acytransferase
inhibitor
inhibitors
dgat2
Prior art date
Application number
ECSENADI202226478A
Other languages
English (en)
Inventor
Kentaro Futatsugi
David James Edmonds
Daniel Jonathan Smaltz
Kevin James Filipski
Michelle Renee Garnsey
Jack Chang Hung Lee
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72826929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP22026478(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP22026478A publication Critical patent/ECSP22026478A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

En la presente se describen compuestos de la Fórmula (I) en donde R1, R2, R3, R4, R5, R6, R7, R8 y R9 se definen en la presente, su uso como inhibidores de diacilglicerol aciltransferasa 2 (DGAT2), composiciones farmacéuticas que contienen dichos inhibidores y el uso de dichos inhibidores para tratar, por ejemplo, NASH.
ECSENADI202226478A 2019-10-04 2022-04-04 Inhibidor de diacilglicerol aciltransferasa 2 ECSP22026478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962911094P 2019-10-04 2019-10-04
US202063074123P 2020-09-03 2020-09-03

Publications (1)

Publication Number Publication Date
ECSP22026478A true ECSP22026478A (es) 2022-05-31

Family

ID=72826929

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202226478A ECSP22026478A (es) 2019-10-04 2022-04-04 Inhibidor de diacilglicerol aciltransferasa 2

Country Status (20)

Country Link
US (2) US11471458B2 (es)
EP (1) EP4038060B1 (es)
JP (1) JP7161081B2 (es)
KR (1) KR20220079906A (es)
CN (1) CN114787146A (es)
AU (1) AU2020358955B2 (es)
CA (1) CA3095028A1 (es)
CL (1) CL2022000835A1 (es)
CO (1) CO2022004286A2 (es)
CR (1) CR20220139A (es)
DO (1) DOP2022000070A (es)
EC (1) ECSP22026478A (es)
ES (1) ES2966340T3 (es)
IL (1) IL291763A (es)
MX (1) MX2022004035A (es)
PE (1) PE20221444A1 (es)
PH (1) PH12022550812A1 (es)
PY (1) PY2060348A (es)
TW (1) TWI771766B (es)
WO (1) WO2021064590A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3953357T1 (sl) 2019-04-12 2024-08-30 Blueprint Medicines Corporation Pirolotriazinski derivati za zdravljenje bolezni, posredovanih s KIT in PDGFRA
JP2022058085A (ja) * 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
EP4225739B1 (en) 2020-10-08 2026-01-21 Merck Sharp & Dohme LLC Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
CR20230160A (es) 2020-10-08 2023-06-02 Merck Sharp & Dohme Llc Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
JP2024501520A (ja) 2020-12-22 2024-01-12 メルク・シャープ・アンド・ドーム・エルエルシー 新規ジアシルグリセリドｏ－アシルトランスフェラーゼ２阻害薬としてのテトラヒドロインダゾール誘導体の調製
CN115429810B (zh) * 2021-06-03 2024-03-08 苏州禾研生物技术有限公司 异黄酮类化合物在制备预防或治疗酒精性肝损伤或解酒保肝的药物中的用途
CN117143008A (zh) * 2022-08-29 2023-12-01 江阴勒森生物科技有限公司 一种3-溴哌啶-1-甲酸叔丁酯的制备方法
AU2023400409A1 (en) 2022-12-02 2025-06-26 Merck Sharp & Dohme Llc Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0580860B2 (en) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
EP1075483B1 (en) 1998-05-04 2003-12-03 Pfizer Products Inc. Hygromycin a derivatives
ATE416772T1 (de) 1998-07-06 2008-12-15 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
BRPI0510284A (pt) 2004-05-12 2007-10-30 Pfizer Prod Inc derivados de prolina e seu uso como inibidores da dipeptidil peptidase iv
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US20110130365A1 (en) 2008-07-29 2011-06-02 Benbow John W Fluorinated Heteroaryls
AP2728A (en) 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
DK2406253T3 (da) 2009-03-11 2013-08-12 Pfizer Benzofuranylderivater anvendt som glucokinase-inhibitorer
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
WO2010121963A1 (en) * 2009-04-21 2010-10-28 Nerviano Medical Sciences S.R.L. Resorcinol derivatives as hsp90 inhibitors
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
AP2799A (en) 2009-06-05 2013-11-30 Pfizer 1-(Piperidin-4-YL)-pyrazole derivatives as GPR 119modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
WO2013137628A1 (ko) 2012-03-16 2013-09-19 한국생명공학연구원 신규한 디아실글리세롤 아실트랜스퍼레이즈 2 억제 물질 및 이의 이용
PE20142164A1 (es) * 2012-04-06 2014-12-27 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
SG11201606779RA (en) 2014-03-17 2016-10-28 Pfizer Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
EP3188732B1 (en) 2014-09-05 2019-07-24 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EP3188730B1 (en) 2014-09-05 2019-05-01 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
US9828369B2 (en) 2014-09-05 2017-11-28 Merck Sharpe & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
KR102314286B1 (ko) 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
JP2022058085A (ja) * 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ

Also Published As

Publication number Publication date
AU2020358955A1 (en) 2022-04-21
PH12022550812A1 (en) 2023-07-17
US20210100798A1 (en) 2021-04-08
TW202126635A (zh) 2021-07-16
EP4038060A1 (en) 2022-08-10
EP4038060B1 (en) 2023-11-15
KR20220079906A (ko) 2022-06-14
WO2021064590A1 (en) 2021-04-08
US20210100796A1 (en) 2021-04-08
AU2020358955B2 (en) 2023-08-17
JP7161081B2 (ja) 2022-10-25
CA3095028A1 (en) 2021-04-04
CN114787146A (zh) 2022-07-22
JP2022543499A (ja) 2022-10-12
TWI771766B (zh) 2022-07-21
DOP2022000070A (es) 2022-05-15
US11065249B2 (en) 2021-07-20
EP4038060C0 (en) 2023-11-15
IL291763A (en) 2022-06-01
US11471458B2 (en) 2022-10-18
ES2966340T3 (es) 2024-04-22
MX2022004035A (es) 2022-05-02
CL2022000835A1 (es) 2023-01-27
CO2022004286A2 (es) 2022-04-29
CR20220139A (es) 2022-05-06
PY2060348A (es) 2022-05-20
PE20221444A1 (es) 2022-09-21

Similar Documents

Publication Publication Date Title
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
GEAP202015005A (en) Diacylglycerol acyltransferase 2 inhibitors
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
CL2020001133A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. (divisional solicitud 201901664)
CO2019003482A2 (es) Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética
BR122021005860A8 (pt) Derivados de aminoácidos e composição que os compreende
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
AR125457A2 (es) Compuestos inhibidores dobles de magl y faah y composición farmacéutica
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
CO2018010787A2 (es) Compuesto de griseofulvina
MX389378B (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
CL2023003921A1 (es) Inhibidores de transglutaminasas
CL2021000282A1 (es) Inhibidores de ckd8/19
MX2025013985A (es) Inhibidores de prmt5
BR112019021323A2 (pt) Inibidores heterocíclicos da biossíntese de lisina através da via do diaminopimelato
CO2022010011A2 (es) Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo
BR112023003744A2 (pt) Composto, e, composição farmacêutica para o tratamento de doenças associadas a diacilglicerol aciltransferase 2
UY38899A (es) Inhibidor de diacilglicerol aciltransferasa 2
ECSP24007534A (es) Inhibidores de transglutaminasas
CL2023003979A1 (es) Inhibidores de las transglutaminasas
BR112022006156A2 (pt) Inibidor de diacilglicerol aciltransferase 2
AR069569A1 (es) Derivados de benzoxazina, un intermediario para su preparacion, una composicion farmaceutica que los comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de renina.